BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 16023790)

  • 21. Bispecific antisense oligonucleotides with multiple binding sites for the treatment of prostate tumors and their applicability to combination therapy.
    Rubenstein M; Tsui P; Guinan P
    Methods Find Exp Clin Pharmacol; 2006 Oct; 28(8):515-8. PubMed ID: 17136230
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis of branched antisense oligonucleotides having multiple specificities. Treatment of hormone insensitive prostate cancer.
    Rubenstein M; Anderson KM; Tsui P; Guinan P
    Med Hypotheses; 2006; 67(6):1375-80. PubMed ID: 16870352
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bispecific antisense oligonucleotides have activity comparable to monospecifics in inhibiting expression of BCL-2 in LNCaP cells.
    Rubenstein M; Guinan P
    In Vivo; 2010; 24(4):489-93. PubMed ID: 20668314
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors.
    Rubenstein M; Tsui P; Guinan P
    Med Oncol; 2007; 24(2):189-96. PubMed ID: 17848743
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antisense oligonucleotide intralesional therapy for human PC-3 prostate tumors carried in athymic nude mice.
    Rubenstein M; Mirochnik Y; Chou P; Guinan P
    J Surg Oncol; 1996 Jul; 62(3):194-200. PubMed ID: 8667627
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Construction of a bispecific antisense oligonucleotide containing multiple binding sites for the treatment of hormone insensitive prostate tumors.
    Rubenstein M; Tsui P; Guinan P
    Med Hypotheses; 2005; 65(5):905-7. PubMed ID: 16023790
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Applications of antisense oligonucleotides in oncology.
    Pierga JY; Magdelenat H
    Cell Mol Biol (Noisy-le-grand); 1994 May; 40(3):237-61. PubMed ID: 7920172
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Not nonsense but antisense--applications of antisense oligonucleotides in different fields of medicine.
    Oberbauer R
    Wien Klin Wochenschr; 1997 Jan; 109(2):40-6. PubMed ID: 9123943
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular therapy to inhibit NFkappaB activation by transcription factor decoy oligonucleotides.
    Morishita R; Tomita N; Kaneda Y; Ogihara T
    Curr Opin Pharmacol; 2004 Apr; 4(2):139-46. PubMed ID: 15063357
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Basics of antisense oligonucleotide therapy and current therapeutical strategies in urology].
    Kausch I; Böhle A
    Aktuelle Urol; 2003 Dec; 34(7):458-68. PubMed ID: 14655082
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antisense oligonucleotides strategy in the treatment of hypertension.
    Kagiyama S; Kagiyama T; Phillips MI
    Curr Opin Mol Ther; 2001 Jun; 3(3):258-64. PubMed ID: 11497350
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antisense tumor therapy (a dream under construction).
    Kopper L; Kovalszky I
    In Vivo; 1994; 8(5):781-6. PubMed ID: 7727725
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antisense therapy in malignant diseases: status quo and quo vadis?
    Tamm I
    Clin Sci (Lond); 2006 Apr; 110(4):427-42. PubMed ID: 16526947
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Androgen axis in prostate cancer.
    Culig Z; Bartsch G
    J Cell Biochem; 2006 Oct; 99(2):373-81. PubMed ID: 16598769
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antisense treatments for biothreat agents.
    Warfield KL; Panchal RG; Aman MJ; Bavari S
    Curr Opin Mol Ther; 2006 Apr; 8(2):93-103. PubMed ID: 16610760
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Antisense oligonucleotides: tools of molecular genetics and therapeutic agents].
    Toulmé JJ; Verspieren P; Boiziau C; Loreau N; Cazenave C; Thuong NT
    Ann Parasitol Hum Comp; 1990; 65 Suppl 1():11-4. PubMed ID: 2264671
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antisense oligonucleotides as therapeutic agents.
    Galderisi U; Cascino A; Giordano A
    J Cell Physiol; 1999 Nov; 181(2):251-7. PubMed ID: 10497304
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.